
Reset all filters
01 3Yupelri
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2022 Revenue in Millions : 202
2021 Revenue in Millions : 162
Growth (%) : 25
Main Therapeutic Indication : Respiratory Diseases
Currency : USD
2023 Revenue in Millions : 221
2022 Revenue in Millions : 202
Growth (%) : 9
Main Therapeutic Indication : Pulmonary/Respiratory Diseases
Currency : USD
2024 Revenue in Millions : 239
2023 Revenue in Millions : 221
Growth (%) : 8